Targeted gene therapy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Melanin biosynthesis is limited to melanocytes partly as a consequence of transcriptional regulation of the enzymes involved in this pathway. Promoter sequences of these enzyme genes may be utilised to drive expression of complementary DNA coding for therapeutic genes so as to provide transcriptional targeting. We have used the 5'-flanking sequences of the murine tyrosinase or tyrosinase-related protein 1 (TRP-1) genes to show that such transcriptional targeting can be achieved both in vitro and in vivo. Using IL-2 as an example of an immunostimulatory gene and Herpes Simplex Virus thymidine kinase (HSVtk) as an example of a prodrug-activating gene we have shown, in murine model systems, that substantial anti-tumour effects can be achieved by targeted gene therapy approaches. The stage now is set for initial clinical evaluations in human patients.

Original languageEnglish (US)
Pages (from-to)647-655
Number of pages9
JournalBritish Medical Bulletin
Volume51
Issue number3
StatePublished - 1995
Externally publishedYes

Fingerprint

Genetic Therapy
Genes
Monophenol Monooxygenase
Thymidine Kinase
5' Flanking Region
Melanocytes
Melanins
Prodrugs
Simplexvirus
Enzymes
Interleukin-2
Complementary DNA
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hart, I. R., & Vile, R. G. (1995). Targeted gene therapy. British Medical Bulletin, 51(3), 647-655.

Targeted gene therapy. / Hart, I. R.; Vile, Richard Geoffrey.

In: British Medical Bulletin, Vol. 51, No. 3, 1995, p. 647-655.

Research output: Contribution to journalArticle

Hart, IR & Vile, RG 1995, 'Targeted gene therapy', British Medical Bulletin, vol. 51, no. 3, pp. 647-655.
Hart, I. R. ; Vile, Richard Geoffrey. / Targeted gene therapy. In: British Medical Bulletin. 1995 ; Vol. 51, No. 3. pp. 647-655.
@article{78219ea8d55e486b819712141253c454,
title = "Targeted gene therapy",
abstract = "Melanin biosynthesis is limited to melanocytes partly as a consequence of transcriptional regulation of the enzymes involved in this pathway. Promoter sequences of these enzyme genes may be utilised to drive expression of complementary DNA coding for therapeutic genes so as to provide transcriptional targeting. We have used the 5'-flanking sequences of the murine tyrosinase or tyrosinase-related protein 1 (TRP-1) genes to show that such transcriptional targeting can be achieved both in vitro and in vivo. Using IL-2 as an example of an immunostimulatory gene and Herpes Simplex Virus thymidine kinase (HSVtk) as an example of a prodrug-activating gene we have shown, in murine model systems, that substantial anti-tumour effects can be achieved by targeted gene therapy approaches. The stage now is set for initial clinical evaluations in human patients.",
author = "Hart, {I. R.} and Vile, {Richard Geoffrey}",
year = "1995",
language = "English (US)",
volume = "51",
pages = "647--655",
journal = "British Medical Bulletin",
issn = "0007-1420",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Targeted gene therapy

AU - Hart, I. R.

AU - Vile, Richard Geoffrey

PY - 1995

Y1 - 1995

N2 - Melanin biosynthesis is limited to melanocytes partly as a consequence of transcriptional regulation of the enzymes involved in this pathway. Promoter sequences of these enzyme genes may be utilised to drive expression of complementary DNA coding for therapeutic genes so as to provide transcriptional targeting. We have used the 5'-flanking sequences of the murine tyrosinase or tyrosinase-related protein 1 (TRP-1) genes to show that such transcriptional targeting can be achieved both in vitro and in vivo. Using IL-2 as an example of an immunostimulatory gene and Herpes Simplex Virus thymidine kinase (HSVtk) as an example of a prodrug-activating gene we have shown, in murine model systems, that substantial anti-tumour effects can be achieved by targeted gene therapy approaches. The stage now is set for initial clinical evaluations in human patients.

AB - Melanin biosynthesis is limited to melanocytes partly as a consequence of transcriptional regulation of the enzymes involved in this pathway. Promoter sequences of these enzyme genes may be utilised to drive expression of complementary DNA coding for therapeutic genes so as to provide transcriptional targeting. We have used the 5'-flanking sequences of the murine tyrosinase or tyrosinase-related protein 1 (TRP-1) genes to show that such transcriptional targeting can be achieved both in vitro and in vivo. Using IL-2 as an example of an immunostimulatory gene and Herpes Simplex Virus thymidine kinase (HSVtk) as an example of a prodrug-activating gene we have shown, in murine model systems, that substantial anti-tumour effects can be achieved by targeted gene therapy approaches. The stage now is set for initial clinical evaluations in human patients.

UR - http://www.scopus.com/inward/record.url?scp=0029094952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029094952&partnerID=8YFLogxK

M3 - Article

C2 - 7552086

AN - SCOPUS:0029094952

VL - 51

SP - 647

EP - 655

JO - British Medical Bulletin

JF - British Medical Bulletin

SN - 0007-1420

IS - 3

ER -